Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2017-08-30 Annual Report
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Appendix 4E & Preliminary Final Report 69 pages 682.6KB
Annual Report Classification · 98% confidence The document is titled 'Appendix 4E Preliminary Final Report' and includes detailed financial statements and notes for the year ended 30 June 2017. It contains a Directors' Report, Consolidated Statements of Profit or Loss, Financial Position, Cash Flow, and an Independent Auditor's Report. The content is comprehensive, covering the full fiscal year financial performance and corporate information. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of audited financial statements and detailed operational and financial review confirms this is the official annual report. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2017
2017-08-30 English
FY17 Full Year Results Announcement 5 pages 599.3KB
Annual Report Classification · 95% confidence The document is an ASX announcement dated 31 August 2017 presenting detailed financial results for the year ended 30 June 2017. It includes comprehensive financial data such as revenue, gross profit, EBITDA loss, cash flow, segment revenues, and business reviews. The document discusses full year sales, margins, expenses, and outlook, which are typical contents of an annual financial report. The length of the document (11,836 characters) and the presence of detailed financial tables and analysis indicate this is the full financial report rather than a brief announcement or a notice of report publication. Therefore, this document fits the definition of an Annual Report (10-K equivalent) rather than an Earnings Release or Regulatory Filing. Hence, the appropriate classification is Annual Report (10-K). FY 2017
2017-08-30 English
Exclusive Supply Agreement with 4C Medical 2 pages 129.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 31 August 2017, titled 'ADMEDUS ANNOUNCES EXCLUSIVE SUPPLY AGREEMENT WITH 4C MEDICAL.' It details a business agreement between Admedus Limited and 4C Medical Technologies regarding supply of tissue engineering products. The content focuses on the announcement of a commercial partnership and product supply agreement, with no financial data, regulatory filings, or report references. It is not a financial report, earnings release, management discussion, or regulatory filing. The document is a corporate announcement about a supply agreement, which fits best under Capital/Financing Update (CAP) as it relates to business development and potential revenue streams from a new agreement.
2017-08-30 English
Appendix 4C - quarterly 8 pages 592.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Admedus Limited Quarterly report - Appendix 4C for period to 30 June 2017' and includes detailed quarterly financial data such as cash flows from operating, investing, and financing activities, as well as operational highlights and financial highlights for the quarter ending 30 June 2017. It references compliance with Listing Rule 4.7B and includes a compliance statement. The document is approximately 13,737 characters long, indicating it is a substantive report rather than a brief announcement. The content and format align with a quarterly financial report providing actual financial statements and analysis for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q4 2017
2017-07-25 English
Update on the CardioCel 3D Product Launch 1 page 14
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 7 July 2017 from Admedus Limited regarding an update on the CardioCel 3D product launch. It discusses the progress and plans for the product's phased commercial introduction and includes contact information and company background. There are no financial statements, regulatory filings, voting results, or detailed financial data. The document is relatively short (1922 characters) and serves as a business update rather than a formal report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a general company announcement about product development progress, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2017-07-06 English
Admedus Appoints Chief Operating Officer 2 pages 245.3KB
Board/Management Information Classification · 100% confidence The document is a company announcement about the appointment of a new Chief Operating Officer. It contains no financial data, no report or regulatory filing references, and no mention of shareholder votes or capital changes. It is an announcement related to senior management changes, specifically naming the new COO and the outgoing COO. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on management appointment, confirming it is not a full report or financial release.
2017-06-08 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.